MAP2K4

MAP2K4

A gene on chromosome 17q11.2 that encodes a MAPK kinase belonging to a protein kinase signal transduction cascade. MAP2K4 is a dual-specificity kinase and an essential component of the MAP kinase signal transduction pathway. It is also an essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway, which is involved in the mitochondrial death signalling pathway, including the release cytochrome c, leading to apoptosis. With MAP2K7/MKK7, it is the only known kinase to directly activate the SAP/JNKs MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3; whereas MAP2K7/MKK7 exclusively activates JNKs, MAP2K4/MKK4 also activates the p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14. MAP2K4 is required for maintaining peripheral lymphoid homeostasis. It is widely expressed in tissues, especially in skeletal muscle.
References in periodicals archive ?
Importantly, APAF1 and MAP2K4, together with 2 other upregulated genes, deleted in liver cancer 1 (DLC1) and N-myristoyltransferase 1 (NMT1), participate in the cytoplasmic/mitochondrial transport of the proapoptotic proteins Bid, Bmf, and Bim.
Within this pathway, 4 genes were significantly upregulated in RPs and 3 of them were the predicted targets of the 5 miRNAs (APAF1, MAP2K4, and NMT1) (Fig.
In contrast, mutations in MAP3K1 and its "sister" gene MAP2K4 occurred in about 16 percent of patients and were linked to a good response to aromatase inhibitors.
In addition, the MAP2K4 (mitogen-activated protein kinase kinase 4) gene, located in 17p, was selected as a control (i.
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.